NCT03433001 · OUTCOME

Rate of Minimal Residual Disease (MRD) Negativity in Bone Marrow in Participants Who Achieved CR

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone · Source last updated 2023-12-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of Participants
Interval / dispersion: Not reported
Time frame: Up to 36 months as a maximum

What was measured

Rate of MRD will be calculated by the percentage of participants who are MRD-negative.

Analysis population: Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.

Groups in this outcome

Ixazomib + Lenalidomide + Dexamethasone

Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Ixazomib + Lenalidomide + Dexamethasone	68

Reported measurements

10^-4=< - Max

Values in Percentage of Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Ixazomib + Lenalidomide + Dexamethasone	26.7	Not reported	Not reported	Not reported	Not reported

10^-5=< - <10^-4

Values in Percentage of Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Ixazomib + Lenalidomide + Dexamethasone	16.7	Not reported	Not reported	Not reported	Not reported

10^-6=< - <10^-5

Values in Percentage of Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Ixazomib + Lenalidomide + Dexamethasone	6.7	Not reported	Not reported	Not reported	Not reported

Negative

Values in Percentage of Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Ixazomib + Lenalidomide + Dexamethasone	50.0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
26.7
title
10^-4=< - Max
categories
measurements
group Id
OG000
value
16.7
title
10^-5=< - <10^-4
categories
measurements
group Id
OG000
value
6.7
title
10^-6=< - <10^-5
categories
measurements
group Id
OG000
value
50.0
title
Negative

denoms

counts
group Id
OG000
value
68
units
Participants

description

Rate of MRD will be calculated by the percentage of participants who are MRD-negative.

groups

description
Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.
id
OG000
title
Ixazomib + Lenalidomide + Dexamethasone

param Type

NUMBER

population Description

Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.

reporting Status

POSTED

time Frame

Up to 36 months as a maximum

title

Rate of Minimal Residual Disease (MRD) Negativity in Bone Marrow in Participants Who Achieved CR

type

SECONDARY

unit Of Measure

Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice